Dose Finding, Efficacy and Immunological Response of IP-001 Following MWA or IRE for CRLM

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

Netherlands

Amsterdam UMC - location VUmc, Amsterdam, North Holland